Skip to content

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

Home
About Us
Office
E-Library
Research Support
Blog
Donation
Contact Us

January 27, 2026

New Releases from NCBI BookshelfFederal Policies and Public Reimbursement of Pediatric Medicines in Canada: Drugs, Health Systems [Internet].Federal Policies and Public Reimbursement of Pediatric Medicines in Canada: Drugs, Health Systems [Internet].

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfChildren’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care.Children’s attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care.

Leave a Comment / Uncategorized / admin

Post Content

New Releases from NCBI BookshelfVorasidenib (Voranigo): Indication: For the treatment of Grade 2 (World Health Organization [WHO] 2016, 2021 grading system) astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention: Reimbursement Recommendation [Internet].Vorasidenib (Voranigo): Indication: For the treatment of Grade 2 (World Health Organization [WHO] 2016, 2021 grading system) astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and older following surgical intervention: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

Canada’s Drug Agency (CDA-AMC) recommends that Voranigo be reimbursed by public drug plans for patients aged 12 years and older

New Releases from NCBI BookshelfIbrutinib: Reimbursement Recommendation [Internet].Ibrutinib: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized / admin

The Formulary Management Expert Committee (FMEC) recommends that ibrutinib in combination with immunochemotherapy with or without autologous stem cell transplant

New Releases from NCBI BookshelfQuizartinib (Vanflyta): Therapeutic area: Acute myeloid leukemia: Reimbursement Review [Internet].Quizartinib (Vanflyta): Therapeutic area: Acute myeloid leukemia: Reimbursement Review [Internet].

Leave a Comment / Uncategorized / admin

Post Content

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top